Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oxurion NV (GB:0G99)
LSE:0G99
Oxurion NV (0G99) Share Price & Analysis
0 Followers
0G99 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range― - ―
Previous Close€0.01
Volume0.00
Average Volume (3M)N/A
Market Cap
€1.80M
Enterprise Value€6.23M
Total Cash (Recent Filing)€3.59M
Total Debt (Recent Filing)€8.02M
Price to Earnings (P/E)-0.4
Beta-0.09
Next Earnings
Sep 30, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares OutstandingN/A
10 Day Avg. Volume164
30 Day Avg. VolumeN/A
Standard Deviation0.15
R-Squared0.04
Alpha0.00910
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.03% Mutual Funds
0.00% Other Institutional Investors
99.97% Public Companies and
Individual Investors
0G99 FAQ
What was Oxurion NV’s price range in the past 12 months?
Currently, no data Available
What is Oxurion NV’s market cap?
Currently, no data Available
When is Oxurion NV’s upcoming earnings report date?
Oxurion NV’s upcoming earnings report date is Sep 30, 2024 which is in 144 days.
How were Oxurion NV’s earnings last quarter?
Oxurion NV released its earnings results on Apr 15, 2024. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.002.
Is Oxurion NV overvalued?
According to Wall Street analysts Oxurion NV’s price is currently Overvalued.
Does Oxurion NV pay dividends?
Oxurion NV does not currently pay dividends.
What is Oxurion NV’s EPS estimate?
Oxurion NV’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxurion NV have?
Oxurion NV has 9,014,821,000 shares outstanding.
What happened to Oxurion NV’s price movement after its last earnings report?
Oxurion NV reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Oxurion NV?
Currently, no hedge funds are holding shares in GB:0G99
---
Oxurion NV Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-45.38%
Trailing 12-Months
Company Description
Oxurion NV
Oxurion NV is a biopharmaceutical company. The company is focused on developing treatments to preserve vision for patients with diseases affecting the back of the eye. It has developed a diverse portfolio of disease-modifying drug candidates, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide. It owns the global rights to Jetrea (ocriplasmin), the pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the U.S.) and vitreomacular traction (outside the U.S.).
---
0G99 Stock 12 Month Forecast
Average Price Target
―---